---
figid: PMC9518657__fphar-13-938650-g001
figtitle: 'Control of aging by the renin–angiotensin system: a review of C. elegans,
  Drosophila, and mammals'
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC9518657
filename: fphar-13-938650-g001.jpg
figlink: /pmc/articles/PMC9518657/figure/F1/
number: F1
caption: Pharmacological inhibition of the renin–angiotensin system influences aging
  in C. elegans, Drosophila, and mammals. (A) The RAS pathway in mammals; the ACE
  inhibitor Enalapril and angiotensin II type-1 receptor blocker Losartan are FDA-approved
  drugs that control aging in non-human mammals (see ). AGT, Angiotensinogen; Ang
  I, Angiotensin I; ACE, Angiotensin-converting enzyme; Ang II, Angiotensin II; AGT1R,
  Angiotensin II type-1 receptor; ACE2, Angiotensin-converting enzyme 2; Ang 1-7,
  Angiotensin (1-7); MasR, Mas Receptor. (B) The FDA-approved ACE-inhibitor drug Captopril
  inhibits acn-1, the only C. elegans ACE homolog, to control aging (). ACN-1, Angiotensin-converting
  enzyme-like non-peptidase. (C) The FDA-approved ACE inhibitor drug Lisinopril inhibits
  Ance, the Drosophila ACE homolog, to control aging (). Ance, ANgiotensin-converting
  enzyme. Blue, ACE and its homologs ACE2, Ance, and ACN-1; red, ACE inhibitors (Captopril,
  Enalapril, Lisinopril) or ARBs (Losartan), which have been shown to influence aging.
papertitle: 'Control of aging by the renin–angiotensin system: a review of C. elegans,
  Drosophila, and mammals.'
reftext: Brian M. Egan, et al. Front Pharmacol. 2022;13:938650.
year: '2022'
doi: 10.3389/fphar.2022.938650
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.
keywords: Captopril (ACE-I) | longevity | acn-1 | ACE-angiotensin-converting enzyme
  | Ance | Enalapril | Losartan | Lisinopril
automl_pathway: 0.9282061
figid_alias: PMC9518657__F1
figtype: Figure
redirect_from: /figures/PMC9518657__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9518657__fphar-13-938650-g001.html
  '@type': Dataset
  description: Pharmacological inhibition of the renin–angiotensin system influences
    aging in C. elegans, Drosophila, and mammals. (A) The RAS pathway in mammals;
    the ACE inhibitor Enalapril and angiotensin II type-1 receptor blocker Losartan
    are FDA-approved drugs that control aging in non-human mammals (see ). AGT, Angiotensinogen;
    Ang I, Angiotensin I; ACE, Angiotensin-converting enzyme; Ang II, Angiotensin
    II; AGT1R, Angiotensin II type-1 receptor; ACE2, Angiotensin-converting enzyme
    2; Ang 1-7, Angiotensin (1-7); MasR, Mas Receptor. (B) The FDA-approved ACE-inhibitor
    drug Captopril inhibits acn-1, the only C. elegans ACE homolog, to control aging
    (). ACN-1, Angiotensin-converting enzyme-like non-peptidase. (C) The FDA-approved
    ACE inhibitor drug Lisinopril inhibits Ance, the Drosophila ACE homolog, to control
    aging (). Ance, ANgiotensin-converting enzyme. Blue, ACE and its homologs ACE2,
    Ance, and ACN-1; red, ACE inhibitors (Captopril, Enalapril, Lisinopril) or ARBs
    (Losartan), which have been shown to influence aging.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - agt
  - ace
  - fgf8a
  - ace2
  - AGT
  - AGXT
  - ACE
  - ACE2
---
